Inscrição na biblioteca: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Publicou 6 edições por ano

ISSN Imprimir: 0743-4863

ISSN On-line: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Immunological and Toxicological Implications of Short-Term Studies in Animals of Pharmaceutical Aerosol Delivery to the Lungs: Relevance to Humans

Volume 18, Edição 4, 2001, 45 pages
DOI: 10.1615/CritRevTherDrugCarrierSyst.v18.i4.20
Get accessGet access

RESUMO

The effects of xenobiotics on the lungs have been studied for many years. In the past 50 years, delivery of drugs to the lungs has been adopted to achieve local effects, specifically for the treatment of asthma. Recently, due to the proximity of the circulating blood supply and to their large surface area, the lungs have been proposed as the port of entry for drugs to obtain systemic effects, particularly for macromolecular compounds of biological origin. Numerous studies regarding drug formulation, delivery systems, and related pharmacokinetics have been reported; however, the concurrent effects of pulmonary delivery of drugs on the physiology of the lung has not been evaluated early in the development process. The prospect of using the lungs for the delivery of biological molecules such as proteins, peptides, and nucleic acids raises the question of the local toxicity of these compounds. Therefore, criteria must be established to study the initial impact of pulmonary drug delivery on the physiology of the lungs. This relates particularly to subtle local and systemic implications of those effects on the transport phenomena that may be contrasted with conventional toxicity studies focused on gross effects.

CITADO POR
  1. Bai Shuhua, Thomas Chandan, Ahsan Fakhrul, Dendrimers as a Carrier for Pulmonary Delivery of Enoxaparin, a Low-Molecular Weight Heparin, Journal of Pharmaceutical Sciences, 96, 8, 2007. Crossref

  2. Cryan Sally-Ann, Carrier-based strategies for targeting protein and peptide drugs to the lungs, The AAPS Journal, 7, 1, 2005. Crossref

  3. Rawat Amit, Yang Tianzhi, Hussain Alamdar, Ahsan Fakhrul, Complexation of a Poly-l-Arginine with Low Molecular Weight Heparin Enhances Pulmonary Absorption of the Drug, Pharmaceutical Research, 25, 4, 2008. Crossref

  4. Hamishehkar Hamed, Emami Jaber, Najafabadi Abdolhossien Rouholamini, Gilani Kambiz, Minaiyan Mohsen, Hassanzadeh Kambiz, Mahdavi Hamid, Koohsoltani Maryam, Nokhodchi Ali, Pharmacokinetics and pharmacodynamics of controlled release insulin loaded PLGA microcapsules using dry powder inhaler in diabetic rats, Biopharmaceutics & Drug Disposition, 2010. Crossref

  5. Fujita Yu, Takeshita Fumitaka, Kuwano Kazuyoshi, Ochiya Takahiro, RNAi Therapeutic Platforms for Lung Diseases, Pharmaceuticals, 6, 2, 2013. Crossref

  6. Hussain Alamdar, Majumder Quamrul H., Ahsan Fakhrul, Inhaled Insulin is Better Absorbed When Administered as a Dry Powder Compared to Solution in the Presence or Absence of Alkylglycosides, Pharmaceutical Research, 23, 1, 2006. Crossref

  7. Thomas Chandan, Rawat Amit, Bai Shuhua, Ahsan Fakhrul, Feasibility study of inhaled hepatitis B vaccine formulated with tetradecylmaltoside, Journal of Pharmaceutical Sciences, 97, 3, 2008. Crossref

  8. Amancha Kiran Prakash, Balkundi Shantanu, Lvov Yuri, Hussain Alamdar, Pulmonary sustained release of insulin from microparticles composed of polyelectrolyte layer-by-layer assembly, International Journal of Pharmaceutics, 466, 1-2, 2014. Crossref

  9. Bai Shuhua, Gupta Vivek, Ahsan Fakhrul, Cationic liposomes as carriers for aerosolized formulations of an anionic drug: Safety and efficacy study, European Journal of Pharmaceutical Sciences, 38, 2, 2009. Crossref

  10. Lam Jenny Ka-Wing, Liang Wanling, Chan Hak-Kim, Pulmonary delivery of therapeutic siRNA, Advanced Drug Delivery Reviews, 64, 1, 2012. Crossref

  11. Hussain Alamdar, Ahsan Fakhrul, State of insulin self-association does not affect its absorption from the pulmonary route, European Journal of Pharmaceutical Sciences, 25, 2-3, 2005. Crossref

  12. Nathavitharana Ruvandhi R., Nardell Edward A., Clinical and Public Health Perspectives, in Drug Delivery Systems for Tuberculosis Prevention and Treatment, 2016. Crossref

  13. Morçöl Tülin, Weidner Jessica M., Mehta Anand, Bell Stephen J.D., Block Timothy, Calcium Phosphate Particles as Pulmonary Delivery System for Interferon-α in Mice, AAPS PharmSciTech, 19, 1, 2018. Crossref

  14. Nawroth Janna C., Barrile Riccardo, Conegliano David, van Riet Sander, Hiemstra Pieter S., Villenave Remi, Stem cell-based Lung-on-Chips: The best of both worlds?, Advanced Drug Delivery Reviews, 140, 2019. Crossref

  15. Khan Muhammad Suleman, Roberts Michael S., Challenges and innovations of drug delivery in older age, Advanced Drug Delivery Reviews, 135, 2018. Crossref

  16. Garcia-Contreras Lucila, In Vivo Animal Models for Controlled-Release Pulmonary Drug Delivery, in Controlled Pulmonary Drug Delivery, 2011. Crossref

  17. Wiedmann Timothy S., Wattenberg Lee W., Chemoprevention of Cancer of the Respiratory Tract by Agents Delivered by Aerosol, in Cancer Chemoprevention, 2004. Crossref

  18. Durcan Niamh, Murphy Charlotte, Cryan Sally-Ann, Inhalable siRNA: Potential as a Therapeutic Agent in the Lungs, Molecular Pharmaceutics, 5, 4, 2008. Crossref

  19. Garcia-Contreras Lucila, Smyth Hugh D C, Liquid-Spray or Dry-Powder Systems for Inhaled Delivery of Peptide and Proteins?, American Journal of Drug Delivery, 3, 1, 2005. Crossref

  20. Deshmukh Rohitas, Bandyopadhyay Nabamita, Abed Sara Nidal, Bandopadhyay Shantanu, Pal Yogendra, Deb Pran Kishore, Strategies for pulmonary delivery of drugs, in Drug Delivery Systems, 2020. Crossref

  21. Kim Junghyun, Jeon Seulgi, Kang Seong Jae, Kim Kyoung-Ran, Thai Hien Bao Dieu, Lee Seokyung, Kim Sehoon, Lee Yun-Sil, Ahn Dae-Ro, Lung-targeted delivery of TGF-β antisense oligonucleotides to treat pulmonary fibrosis, Journal of Controlled Release, 322, 2020. Crossref

  22. Kandil Rima, Merkel Olivia M, Pulmonary delivery of siRNA as a novel treatment for lung diseases, Therapeutic Delivery, 10, 4, 2019. Crossref

  23. Bardoliwala Denish, Patel Vivek, Javia Ankit, Ghosh Saikat, Patel Akanksha, Misra Ambikanandan, Nanocarriers in effective pulmonary delivery of siRNA: current approaches and challenges, Therapeutic Delivery, 10, 5, 2019. Crossref

Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain